Scientist have been able to link the insufficient production of metabolites in the gut to a number of common diseases such as inflammatory bowel disease, diabetes type-2, neurological diseases and different forms of cancer. Recent scientific progress in the field has sparked an interest from the pharmaceutical industry, consumers och and food producers. Carbiotix, based i Lund, is a company focusing on gut health by providing a diagnostics platform and their proprietary prebiotic fiber Carbiotix AXOS. BioStock has published a status report on Carbiotix.
Evolving from a promising and award-winning start up company, Carbiotix was listed on Spotlight Stock Market in October 2019. The subscription price was set to SEK 4,45 per share, bringing the total capital raised to SEK 12 million and at pre money valuation of SEK 25,8 million. At the time of publication of the status report, the company had a market cap of SEK 23 million.
The company has had a rapid development pace and by February, CEO Kristofer Cook, announced that the company would be ready to launch a prebiotic modulator therapy three years earlier than originally anticipated, with several additional milestones expected to be achieved during the year.
Download BioStock’s status report here.
This analysis is a Status Report by BioStock, conducted on commission by the analysed company. BioStock’s remuneration for the work has been agreed upon beforehand and is independent of the content and conclusions reached in the analysis. The content of this analysis is based solely on publicly available information gathered through research by the analyst from sources such as e.g. financial reports and statements, the company’s web page, public presentations and in dialogue with representatives of the company’s executive management. The information about the company was made available to the company for fact-checking and was published subsequent approval by the company. The analysis contains subjective assessments regarding future events and outcomes which should be considered to render such assessments to be uncertain. Any valuation of the company, products and/or markets has been made by BioStock’s analyst. The analyst does not own shares in the company. This analysis should not be considered as a recommendation or advice to invest in the company nor shall it be interpreted as financial advice of any sort. BioStock can not and does not give any guarantees that the conclusions or forecasts presented in this analysis will be fulfilled. BioStock can not be held responsible or liable for any damage, direct or indirect, caused by decisions made based on the information in this analysis. BioStock is not subject to the oversight of the Swedish financial authority Finansinspektionen and is thus not required to comply with the specific rules and guidelines that apply to analysis firms subject to the oversight of Finansinspektionen.